Regorafenib + Anti-EGFR Therapy for Colorectal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the effectiveness of combining regorafenib with anti-EGFR therapy (cetuximab or panitumumab) for treating colorectal cancer that cannot be surgically removed and has spread locally or to other parts of the body. The study examines the effects of taking regorafenib (a targeted cancer therapy) followed by cetuximab or panitumumab, and vice versa. Individuals with advanced or metastatic colorectal cancer who have not previously received these specific drugs might be suitable candidates. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering a chance to benefit from innovative therapies.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, if you are on blood thinners like warfarin or heparin, you can still participate with close monitoring. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that regorafenib is FDA-approved for treating advanced colorectal cancer, indicating it has undergone safety testing in people. In earlier studies, regorafenib was generally well-tolerated, though some patients experienced side effects like tiredness and skin reactions on their hands and feet.
Cetuximab has also undergone extensive study. It is usually well-tolerated, but about 3% of patients experienced serious reactions during administration.
Panitumumab has been tested in several clinical trials. It appears generally safe, though some patients have experienced skin reactions and other side effects.
Irinotecan is effective but can cause severe side effects like diarrhea and low white blood cell counts, requiring close patient monitoring.
Overall, these treatments have been tested in various trials. While they can cause side effects, they are generally considered safe when managed properly.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for colorectal cancer because they offer new ways to tackle the disease. Regorafenib is unique because it targets multiple pathways that help cancer cells grow, making it different from standard treatments that usually focus on just one pathway. On the other hand, combining cetuximab or panitumumab with irinotecan brings a fresh approach by using targeted therapy along with chemotherapy, potentially enhancing the effectiveness against tumors. These innovative strategies could provide more options and hope for patients who don't respond well to existing therapies.
What evidence suggests that this trial's treatments could be effective for colorectal cancer?
This trial will compare two treatment approaches for advanced colorectal cancer. Studies have shown that regorafenib, which participants in Arm A may receive, can extend patient survival by blocking proteins that promote cancer cell growth. In Arm B, participants may receive a combination of cetuximab or panitumumab with irinotecan. Research has shown that this combination effectively treats colorectal cancer, particularly in patients with specific genetic traits. Cetuximab and panitumumab are antibodies that inhibit cancer cell growth and spread. These treatments have proven successful in patients with colorectal cancer, especially those with certain genetic profiles. Together, these approaches offer promising options for managing advanced colorectal cancer.678910
Who Is on the Research Team?
Daniel H Ahn
Principal Investigator
Academic and Community Cancer Research United
Are You a Good Fit for This Trial?
This trial is for adults with advanced colorectal cancer that can't be removed by surgery, has spread, and hasn't responded to certain treatments. Participants must have a life expectancy of at least 3 months, adequate organ function, no severe concurrent diseases or recent significant cardiovascular events. Pregnant or breastfeeding women are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive regorafenib or anti-EGFR monoclonal antibody therapy, with cycles repeating every 28 days until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Cetuximab
- Irinotecan
- Panitumumab
- Regorafenib
Trial Overview
The study tests regorafenib in combination with anti-EGFR therapy (cetuximab or panitumumab) versus the reverse order for metastatic colorectal cancer treatment. It aims to see which sequence works better for controlling cancer growth.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.
Cetuximab is already approved in United States, European Union for the following indications:
- Locally or regionally advanced squamous cell carcinoma of the head and neck
- Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck
- K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer
- BRAF V600E mutation-positive metastatic colorectal cancer
- Squamous cell carcinoma of the head and neck
- K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Academic and Community Cancer Research United
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
Triplet‐drug chemotherapy combined with anti‐EGFR ...
Our findings show that triplet-drug chemotherapy (FOLFOXIRI) combined with anti-EGFR antibody (panitumumab or cetuximab) represents a very effective ...
Molecular subtype-specific efficacy of anti-EGFR therapy in ...
For CMS2/3 patients there was indeed a better outcome when cetuximab was added to FOLFOX, though this was not significant (PFS HR 0.45, 95% CI ...
Chemotherapy plus Panitumumab Versus ...
Panitumumab and bevacizumab have been widely used in combination with chemotherapy for patients with wild type RAS metastatic colorectal cancer (mCRC).
Panitumumab versus cetuximab in combination with ...
Previous data showed clinically significant activity of cetuximab in combination with irinotecan in patients with irinotecan-refractory colorectal cancer, with ...
WT RAS mCRC Study Results & Efficacy
Explore study data establishing the efficacy of Vectibix® for newly diagnosed and chemorefractory patients with WT RAS mCRC. See Prescribing and Safety Info ...
ERBITUX (cetuximab) - accessdata.fda.gov
The data described below reflect exposure to ERBITUX in 242 patients with K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) [see Warnings ...
Metastatic Colorectal Cancer | mCRC | HCP - Erbitux - Eli Lilly
ERBITUX provides approximately 22% higher exposure compared to the cetuximab product used in CRYSTAL; however, the safety data from CRYSTAL is consistent in ...
An Update of Efficacy and Safety of Cetuximab in ...
Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of ...
FDA Approves ERBITUX(R) (cetuximab) as First-Line ...
Serious infusion reactions occurred with the administration of ERBITUX in approximately 3 percent of patients in clinical trials, with fatal ...
Cetuximab (Erbitux) - Medical Clinical Policy Bulletins
Safety data from the 111 patients treated only with cetuximab ... Cetuximab (Erbitux) for metastatic colorectal cancer: Horizon scanning technology briefing.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.